



Vaccine research can
help our children SOAR
beyond COVID-19.



Now enrolling: The HUMMINGBIRD pediatric COVID-19 vaccine study

The HUMMINGBIRD study is testing an investigational vaccine that is designed to prevent coronavirus disease 2019 (COVID-19). The study vaccine is a protein-based (or traditional) vaccine and is not an mRNA vaccine. NVX-CoV2373 has been authorized in various countries for adolescents and adults 12 years of age and older. Now, researchers are evaluating it for children ages 6 months to 11 years.

To be eligible for this study, your child must:

- Be 6 months to 11 years of age
- Have never been diagnosed with COVID-19
- Not have received a previous vaccine to protect against COVID-19

This is not a complete list of eligibility criteria. The study doctor will review the full entry criteria for this study with you.

Ask your doctor about the HUMMINGBIRD study, visit novavaxpediatricvaccine.com, or scan the QR code.

To learn more about the
HUMMINGBIRD pediatric COVID-19
vaccine study, contact:

1-888-788-0644 vturesearch@msm.edu



2019nCoV-503_flyer_v1.0_22Apr2022_ENG

